Advertisement

Familial Cancer

, Volume 17, Issue 2, pp 209–212 | Cite as

A new hereditary colorectal cancer network in the Middle East and eastern mediterranean countries to improve care for high-risk families

  • Zeinab Ghorbanoghli
  • Carol Jabari
  • Walid Sweidan
  • Wail Hammoudeh
  • George Cortas
  • Ala I. Sharara
  • Amal Abedrabbo
  • Ijad Hourani
  • Bahareh Mahjoubi
  • Keivan Majidzadeh
  • Nurdan Tözün
  • Hadia Ziada-Bouchaar
  • Waseem Hamoudi
  • Osama Diab
  • Hamid Reza Khorram Khorshid
  • Henry Lynch
  • Hans Vasen
Open Access
Short Communication
  • 784 Downloads

Abstract

Colorectal cancer (CRC) has a very high incidence in the western world. Data from registries in the Middle East showed that the incidence of CRC is relatively low in these countries. However, these data also showed that CRC incidence has increased substantially over the past three decades and that a high proportion of cases are diagnosed at an early age (<50 years). In view of these findings, more attention should be paid to prevention. Because of the often limited financial resources, focused screening of individuals with hereditary CRC, in particular those with Lynch syndrome, appears to be the most cost-effective strategy. During recent meetings of the Palestinian Society of Gastroenterology and the Mediterranean Task force for Cancer Control (MTCC) in Jericho, and the Patient’s Friends Society of Jerusalem in Hebron the issue of hereditary CRC in the Middle East was discussed and the idea was conceived to establish a network on hereditary colorectal cancer (HCCN-ME) with the goal of improving care for high-risk groups in the Middle East and (Eastern) Mediterranean Countries.

Keywords

Lynch syndrome Familial colorectal cancer CMMRD Health care Identification Registry 

Introduction

In the western world, colorectal cancer (CRC) has a very high incidence, occupying the second or third position on the list of commonest cancers in most countries (http://Globocan.iarc.fr). Detailed information on the epidemiology of CRC in the Middle East is limited to the few cancer registries currently in existence. Data from the Gharbia registry (Egyptian region with 4 million inhabitants) showed that the incidence of CRC is relatively low (5/100,000), with higher rates in urban areas compared to rural areas [1]. Data from the Israel National Cancer Registry confirms the low incidence of CRC in the Arab population (Israel National Cancer Registry website). However, data from this registry also showed that CRC incidence has increased substantially over the past three decades, with the age standardized rate (ASR) increasing from 5.5/100,000 in the 1980s to around 20/100,000 in 2013.

An interesting characteristic of the epidemiology of CRC in the Middle East is the high proportion of cases that are diagnosed at an early age. For example, 24% of the CRC cases in the Gharbia district in Egypt and 25% of CRC cases in Iran were diagnosed before ages 40 and 45, respectively [1, 2]. These observations may be partly explained by the different age structure of the population, with a higher proportion of the population age <50 in the Middle East compared to the Western countries.

In view of the increasing incidence of CRC and the early onset of CRC in Middle East countries, greater attention should be paid to the prevention of CRC in this region.

Prevention of CRC

In general, two options for prevention of CRC are available: (1) offering screening to the general population using fecal occult blood testing (FOBT), or (2) focusing screening on high risk groups. The first option has already been implemented in many Western countries. Experience with a nationwide FOBT screening program (age: 55–75) that started in the Netherlands in 2014 is very promising. The participation rate is very high (>70% out of 4 million people) and the yield of colonoscopies is substantial, with 8% CRC and >40% advanced adenomas (http://www.rivm.nl). However, a large-scale population-based program is relatively expensive (>80 million Euro’s per year in the Netherlands). In view of the lower incidence of CRC in the Middle East and limited financial resources, focusing screening on high-risk groups might be more cost-effective.

What proportion of CRC in the Middle East is familial or hereditary?

Studies in Western countries have shown that 10–15% of all CRCs are caused by hereditary factors (Fig. 1). About 10% is caused by clustering of CRC in families without an identified high penetrance gene defect, a group referred to as familial colorectal cancer. Approximately 2% is associated with polyposis syndromes, mainly the syndromes caused by mutation(s) in the APC gene (familial adenomatous polyposis) and MUTYH (MUTYH-associated polyposis) [3].

Fig. 1

Etiology of colorectal cancer (CRC)

The most common hereditary CRC syndrome is Lynch syndrome, which is responsible for 3–5% of all CRC cases. This autosomal dominant syndrome is caused by mutations in one of the mismatch repair (MMR) genes (MLH1, MSH2 (EPCAM), MSH6 and PMS2). The main features of the syndrome are (1) an early age of onset of CRC, (2) a high risk of developing multiple tumors, and (3) an association with the development of other cancers (endometrium, ovaries, urinary tract, stomach and other sites). The hallmark of the syndrome is the presence of microsatellite instability (MSI) in the tumor. Several studies from the Middle East reported Lynch syndrome families, and the clinical features of Lynch syndrome families appear to be similar to those seen in Western families [4].

A study from Egypt, focused on obtaining a detailed family history in a series of consecutive patients with CRC, suggested that 7–14% of cases show evidence for familial or hereditary CRC [5]. Other studies evaluated the presence of MMR deficiency in various countries in the Middle East with CRC and found evidence for MMR deficiency in approximately 11–20% of tumors [6, 7, 8]. These data thus suggest that the proportion of familial or hereditary CRC in the Middle East is probably comparable to that in Western countries.

How can Lynch syndrome families be identified in the Middle East?

Obtaining a detailed family history is the most cost-effective approach to identifying familial and hereditary CRC. If facilities for tumor analysis [MSI or immunohistochemical analysis of the MMR-proteins (IHC)] are limited, the classic clinical criteria (revised Amsterdam criteria: 3 CRCs or associated cancers in two successive generations, one cancer diagnosed before age 50 years) [9] can be used to assess whether one is dealing with a Lynch syndrome family. However, families that comply with only some of these criteria should not be excluded from colonoscopic surveillance.

Currently, the best way to identify Lynch syndrome families is by applying MSI analysis or immunohistochemical analysis (IHC) of tumor MMR protein expression. This analysis of CRC tumors can be performed in suspected families based on the main features of Lynch syndrome: early age of onset (<50 years), the occurrence of multiple tumors or clustering of CRC in the family. A relatively new approach is systematic screening by MSI or IHC of all newly diagnosed CRC <70 years, a method that is now being implemented in many Western countries. In addition, an increasing numbers of studies are reporting the testing of multiple cancer-associated genes by next generation sequencing (NGS) [10, 11].

The importance of recognizing CMMRD in the Middle East

A distinct means to identify Lynch syndrome families in the Middle East is through recognition of constitutional mismatch repair deficiency (CMMRD) [12, 13]. This is a very rare autosomal recessive syndrome characterized by the development of multiple tumors in the first and second decade of life. These malignancies include brain tumors, cancer of the colon and small bowel, and hematological malignancies such as leukemia and non-Hodgkin lymphoma. Other features include the development of multiple colorectal adenomas in the second decade of life and the presence of café au lait spots. CMMRD is caused by two germline mutations in the same MMR gene. Marriage between cousins, especially in rural areas, is relatively common in the Middle East and this custom is therefore also likely in families with Lynch syndrome. Parents who are both affected with or predisposed to Lynch syndrome have a 25% risk of having a child who develops CMMRD.

Lynch syndrome should therefore be considered when a child has features of CMMRD (Table 1). However, as the syndrome is typically caused by mutations in PMS2, a gene associated with a relatively low CRC penetrance, CRC might even be absent in family members of a CMMRD patient. CMMRD diagnosis can be made by immunohistochemical analysis of the MMR proteins in both normal and tumor tissue, and by germline mutation analysis.

Table 1

Features of constitutional mismatch repair deficiency (CMMRD) [13]

Feature

Age range at diagnosis (median)

Hematological malignancies

Non-hodgkin lymphoma

0.4–17 (5 years)

Lymphoid leukemia

2–21 (6 years)

Acute myeloid leukemia

6–17 (9.5 years)

Malignant brain and central nervous system tumors

High-grade gliomas

2–40 (9.5 years)

sPNET

4–17 (8 years)

Medulloblastoma

4–12 (7 years)

LS-associated carcinomas

Colon/rectum

8–48 (16 years)

Duodenum/jejunum/ileum

11–42 (28 years)

Endometrium

23–44 (28 years)

Bladder/ureter/renal pelvis/ovaries

unknown

Benign features

Adenomas/polyps of colon, rectum and duodenum

6–46 (14 years)

Café au Lait

 

Middle East network for hereditary CRC

In conclusion, in view of the increasing incidence of CRC in the Middle East and the substantial number of early onset CRC cases, more attention should be paid to prevention. In light of often limited financial resources, focused screening of individuals with hereditary CRC, in particular those with Lynch syndrome, appears to be the most cost-effective strategy.

During recent meetings of the Palestinian Society of Gastroenterology and the Mediterranean Task force for Cancer Control (MTCC) in Jericho, and the Patient’s Friends Society of Jerusalem in Hebron on April 7 and 8, 2017, the issue of hereditary CRC in the Middle East was discussed and the idea was conceived to establish a Middle East Network on Hereditary Colorectal Cancer (HCCN-ME). The main goal of this new Network is to improve care for these high-risk groups in the Middle East and Eastern Mediterranean Countries. Our activities will include (1) an inventory of current care in the countries concerned, (2) development of guidelines for diagnosis and management, (3) development of patient information pamphlets, (4) identification of referral centers for genetic counseling, MSI analysis and DNA analysis in the various countries/regions, (5) establishing registries to guarantee lifetime surveillance, and (6) development of a website. Individuals and organizations in Middle East countries and other (Eastern) Mediterranean countries interested in participating in this network are invited to contact the Secretariat of the network: Dutch Hereditary Colorectal Cancer Registry; Leiden, The Netherlands; hfavasen@stoet.nl. Information on the network can be found at: http://www.hccn-me.com.

Notes

Author contributions

ZG, HFAV: Design of manuscript, ZG, HFAV: Writing of first draft of manuscript, Editing the first draft and approving the final draft of the manuscript: all authors.

References

  1. 1.
    Veruttipong D, Soliman AS, Gilbert SF, Blachley TS, Hablas A, Ramadan M, Rozek LS, Seifeldin IA (2012) Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol 18(30):3997–4003. doi: 10.3748/wjg.v18.i30.3997 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mahdavinia M, Bishehsari F, Ansari R, Norouzbeigi N, Khaleghinejad A, Hormazdi M, Rakhshani N, Malekzadeh R (2005) Family history of colorectal cancer in Iran. BMC Cancer 5:112. doi: 10.1186/1471-2407-5-112 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vasen HF, Tomlinson I, Castells A (2015) Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol 12(2):88–97. doi: 10.1038/nrgastro.2014.229 CrossRefPubMedGoogle Scholar
  4. 4.
    Ziada-Bouchaar H, Sifi K, Filali T, Hammada T, Satta D, Abadi N (2017) First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome. Fam Cancer 16(1):57–66. doi: 10.1007/s10689-016-9917-1 CrossRefPubMedGoogle Scholar
  5. 5.
    Soliman AS, Bondy ML, Levin B, El-Badawy S, Khaled H, Hablas A, Ismail S, Adly M, Mahgoub KG, McPherson RS, Beasley RP (1998) Familial aggregation of colorectal cancer in Egypt. Int J Cancer 77(6):811–816CrossRefPubMedGoogle Scholar
  6. 6.
    Alqahtani M, Grieu F, Carrello A, Amanuel B, Mashour M, Alattas R, Alsaleh K, Alsheikh A, Alqahtani S, Iacopetta B (2016) Screening for Lynch syndrome in young colorectal cancer patients from Saudi Arabia using microsatellite instability as the initial test. Asian Pac J Cancer Prev 17(4):1917–1923CrossRefPubMedGoogle Scholar
  7. 7.
    Siraj AK, Prabhakaran S, Bavi P, Bu R, Beg S, Hazmi MA, Al-Rasheed M, Al-Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, Uddin S, Al-Kuraya KS (2015) Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. Cancer 121(11):1762–1771. doi: 10.1002/cncr.29288 CrossRefPubMedGoogle Scholar
  8. 8.
    Shpitz B, Millman M, Ziv Y, Klein E, Grankin M, Gochberg S, Sandbank J, Halevi A, Bernheim J, Khromov Y, Gutman M, Sayfan J (2006) Predominance of younger age, advanced stage, poorly-differentiated and mucinous histology in Israeli Arab patients with colorectal cancer. Anticancer Res 26(1B):533–537PubMedGoogle Scholar
  9. 9.
    Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMedGoogle Scholar
  10. 10.
    Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S (2015) Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149(3):604–613.e620. doi: 10.1053/j.gastro.2015.05.006 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hechtman JF, Middha S, Stadler ZK, Zehir A, Berger MF, Vakiani E, Weiser MR, Ladanyi M, Saltz LB, Klimstra DS, Shia J (2017) Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Fam Cancer. doi: 10.1007/s10689-017-9993-x Google Scholar
  12. 12.
    Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, Entz-Werle N, Goldberg Y, Ilencikova D, Kratz CP, Lavoine N, Loeffen J, Menko FH, Muleris M, Sebille G, Colas C, Burkhardt B, Brugieres L, Wimmer K (2014) Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet 51(5):283–293. doi: 10.1136/jmedgenet-2013-102238 CrossRefPubMedGoogle Scholar
  13. 13.
    Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, Gerdes AM, Goldberg Y, Ilencikova D, Muleris M, Duval A, Lavoine N, Ruiz-Ponte C, Slavc I, Burkhardt B, Brugieres L (2014) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet 51(6):355–365. doi: 10.1136/jmedgenet-2014-102284 CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Zeinab Ghorbanoghli
    • 1
  • Carol Jabari
    • 2
    • 19
  • Walid Sweidan
    • 3
  • Wail Hammoudeh
    • 4
  • George Cortas
    • 5
  • Ala I. Sharara
    • 6
  • Amal Abedrabbo
    • 7
  • Ijad Hourani
    • 8
  • Bahareh Mahjoubi
    • 9
  • Keivan Majidzadeh
    • 10
  • Nurdan Tözün
    • 11
  • Hadia Ziada-Bouchaar
    • 12
  • Waseem Hamoudi
    • 13
  • Osama Diab
    • 14
  • Hamid Reza Khorram Khorshid
    • 15
  • Henry Lynch
    • 16
  • Hans Vasen
    • 17
    • 18
  1. 1.Department of Gastroenterology and HepatologyLeiden University Medical Centre & Netherlands Foundation for the Detection of Hereditary TumoursLeidenThe Netherlands
  2. 2.Patient’s Friends SocietyJerusalemPalestine
  3. 3.Department of GastroenterologyMakased Islamic Charitable HospitalJerusalemPalestine
  4. 4.Department of Internal MedicineArabcare HospitalRamallahPalestine
  5. 5.Department of Gastroenterology, St. George Hospital Medical CenterUniversity of Balamand Medical SchoolBeirutLebanon
  6. 6.Division of GastroenterologyAmerican University of Beirut Medical CenterBeirutLebanon
  7. 7.Department of PediatricsMakased Islamic Charitable HospitalJerusalemPalestine
  8. 8.Department of SurgeryAgusta Victoria HospitalJerusalemPalestine
  9. 9.Colorectal Research CenterIran University of Medical SciencesTehranIran
  10. 10.Motamed Cancer Institute, ACECRTehranIran
  11. 11.Department of Internal Medicine and GastroenterologyUniversity of Acibadem, Acibadem Kozyatagi HospitalIstanbulTurkey
  12. 12.Laboratory of Biology and Molecular Genetics, Faculty of MedicineUniversity 3ConstantineAlgeria
  13. 13.Department of GastroenterologyThe Royal HospitalAmmanJordan
  14. 14.Department of Internal MedicineCreighton UniversityOmahaUSA
  15. 15.Genetic Research CenterUniversity of Social Welfare and Rehabilitation SciencesTehranIran
  16. 16.Creighton’s Hereditary Cancer CenterCreighton UniversityOmahaUSA
  17. 17.Department of Gastroenterology & HepatologyLeiden University Medical CentreLeidenThe Netherlands
  18. 18.Netherlands Foundation for the Detection of Hereditary TumoursLeidenThe Netherlands
  19. 19.Hebron UniversityHebronPalestine

Personalised recommendations